상세 보기
초록
A cost effective analysis was performed for comparing leflunomide+methotrexate, etanercept monotherapy and etanercept+methotrexate for 6 months. For the patients with methotrexate-resistant RA, ACR20 data were extracted from the published clinical trials searched from Pubmed. The direct medical cost was estimated based on ACR guideline and Korean National Health Insurance reimbursement. Combination therapy of etanercept+methotrexate was found to be more cost-effective than etanercept monotherapy, which meant it was a better therapeutic strategy for methotrexate- resistant RA.
키워드
rheumatoid arthritis; cost-effectiveness analysis; pharmacoeconomics; etanercept
- 제목
- 메토트렉세이트 치료에 실패한 류마티스관절염 환자에서 에타너셉트 사용에 대한 비용-효과 분석
- 제목 (타언어)
- Cost-Effectiveness Analysis of Etanercept in the Treatment of Methotrexate-resistant Rheumatoid Arthritis
- 저자
- 김종구; 박은자; 박세정; 성윤경; 배상철; 이의경
- 발행일
- 2006-04
- 저널명
- 약 학 회 지
- 권
- 50
- 호
- 2
- 페이지
- 70 ~ 77